Try our Advanced Search for more refined results

FEDERAL TRADE COMMISSION v. CEPHALON, INC.

  1. April 06, 2015

    FTC Aims To Limit Cephalon Evidence In Pay-For-Delay Trial

    The Federal Trade Commission launched a bid Friday to keep Cephalon Inc. from introducing certain evidence in a pay-for-delay suit in Pennsylvania federal court over a blockbuster narcolepsy drug, the agency's latest effort to limit evidence as the two sides gear up for trial.

  2. February 18, 2015

    FTC Defends Disgorgement Bid In Cephalon Pay-For-Delay Suit

    The Federal Trade Commission on Tuesday defended its plan to force Cephalon Inc. to turn over billions of dollars in profits it allegedly secured by using a fraudulent patent to pay generic-drug makers to delay launching their own versions of Provigil.

  3. February 03, 2015

    FTC To Get 1st Solo Crack At Cephalon Pay-For-Delay Claims

    A Pennsylvania federal judge said Tuesday that the Federal Trade Commission will get first dibs to prove its pay-for-delay claims against Cephalon Inc. over its Provigil narcolepsy drug before a separate jury trial takes place over similar claims brought by private purchasers.

  4. January 29, 2015

    FTC's Provigil Pay-For-Delay Suit Passes Actavis Test: Judge

    A Pennsylvania federal judge on Wednesday ruled that the Federal Trade Commission's pay-for-delay suit against drugmaker Cephalon Inc. over its Provigil narcolepsy drug meets the U.S. Supreme Court's Actavis standard allowing parties to sue drugmakers over settlements to delay the entry of generic drugs.

  5. September 25, 2014

    Cephalon's Patent Experts Barred In FTC Pay-For-Delay Suit

    A Pennsylvania federal judge on Wednesday barred Cephalon Inc. from having 10 patent experts testify about the risks of its Provigil patent litigation in the Federal Trade Commission's pay-for-delay suit against the drugmaker.

  6. July 30, 2014

    Cephalon Can't Fight IP Battle In FTC Pay-For-Delay Suit

    A Pennsylvania federal judge ruled Tuesday that Cephalon Inc. cannot make arguments about the strength of a Provigil patent in the Federal Trade Commission's pay-for-delay suit against the drugmaker because of an earlier trial finding the patent invalid and unenforceable.

  7. May 06, 2014

    FTC Denied Bid To Add Teva To Cephalon Pay-For-Delay Suit

    A Pennsylvania federal judge overseeing the Federal Trade Commission's pay-for-delay suit against Cephalon Inc. denied the antitrust watchdog's bid Monday to add Teva Pharmaceutical Industries Ltd. to the case after the parties decided to delay the dispute until later in the litigation.

  8. April 07, 2014

    FTC Looks To Ax Cephalon Patent Experts In Antitrust Case

    The Federal Trade Commission urged a Pennsylvania federal court Friday to block Cephalon Inc. from having 10 experts testify about its patent for narcolepsy drug Provigil in the watchdog's pay-for-delay case against the drugmaker, saying the company couldn't relitigate the patent's validity.

  9. January 28, 2014

    FTC Says Cephalon Put Ex-GC's Advice In Play

    The Federal Trade Commission argued Monday in Pennsylvania federal court that Cephalon Inc. had put the testimony of its former general counsel at issue in the antitrust watchdog's pay-for-delay suit, saying the company should either be compelled to turn over the materials or blocked from using them at trial.

  10. January 08, 2014

    Teva Says FTC Can't Draw It Into Pay-For-Delay Case

    Generic drug giant Teva Pharmaceutical Industries Ltd. on Wednesday urged a Pennsylvania federal judge to deny a bid from the Federal Trade Commission to add the company to its antitrust pay-for-delay suit against Provigil maker Cephalon Inc., arguing its acquisition of Cephalon is irrelevant to the case.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!